The Patent Finder
PB

Pardes Biosciences, Inc.

First filing 2021
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Seven patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Apr 2041. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Apr 2041
Next term end
3
Patent families

When these terms end

Each bar runs from grant to computed term end. 2021 to 2043.
US 11,124,497 Inhibitors of Cysteine Proteases and Methods of Use Thereof Apr 14, 2041
US 11,312,704 Inhibitors of Cysteine Proteases and Methods of Use Thereof no later than Apr 14, 2041
US 11,472,793 Inhibitors of Cysteine Proteases and Methods of Use Thereof Apr 14, 2041
US 11,174,231 Inhibitors of Cysteine Proteases and Methods of Use Thereof May 17, 2041
US 11,524,940 Inhibitors of Cysteine Proteases and Methods of Use Thereof May 17, 2041
US 12,145,911 Inhibitors of Cysteine Proteases and Methods of Use Thereof May 17, 2041
US 12,747,230 Inhibitors of Cysteine Proteases and Methods of Use Thereof Jun 25, 2043
20262031203620412043
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
6 pending applications: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Fee deadlines

No maintenance fee falls due on this company's record before Nov 10, 2027.

Recent changes

  • 1 of the patents on this record was granted since Aug 17, 2026

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 7 of 7

PatentTitleStatusExpiresConfidence
US 11,124,497Inhibitors of Cysteine Proteases and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 11,312,704Inhibitors of Cysteine Proteases and Methods of Use Thereof
In force
 · Medium confidence
In forceMedium confidence
US 11,472,793Inhibitors of Cysteine Proteases and Methods of Use Thereof
In force
 · Medium confidence
In forceMedium confidence
US 11,174,231Inhibitors of Cysteine Proteases and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 11,524,940Inhibitors of Cysteine Proteases and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 12,145,911Inhibitors of Cysteine Proteases and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 12,747,230Inhibitors of Cysteine Proteases and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 7: 6 applications pending · 3 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited